Advisors Asset Management Inc. Buys 600,329 Shares of LeMaitre Vascular, Inc. $LMAT

LeMaitre Vascular logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management acquired 600,329 LeMaitre Vascular shares in the third quarter, worth about $49.6 million and representing roughly 2.62% of the company. Institutional investors collectively owned 84.64% of its shares.
  • Quarterly earnings were $0.65 per share, below the $0.69 consensus, while revenue of $67.97 million topped estimates and increased 11.3% year over year.
  • LeMaitre declared a quarterly dividend of $0.25 per share. Analysts’ consensus rating was “Hold,” with a $108.25 average price target.
  • Interested in LeMaitre Vascular? Here are five stocks we like better.

Advisors Asset Management Inc. purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 600,329 shares of the medical instruments supplier's stock, valued at approximately $49,581,000. Advisors Asset Management Inc. owned about 2.62% of LeMaitre Vascular as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in LeMaitre Vascular in the second quarter valued at approximately $314,075,000. First Trust Advisors LP lifted its stake in LeMaitre Vascular by 6.2% during the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier's stock valued at $108,959,000 after acquiring an additional 57,931 shares during the period. Copeland Capital Management LLC lifted its stake in LeMaitre Vascular by 10.1% during the 3rd quarter. Copeland Capital Management LLC now owns 924,081 shares of the medical instruments supplier's stock valued at $76,320,000 after acquiring an additional 84,618 shares during the period. Boston Trust Walden Corp purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at $28,546,000. Finally, Voya Investment Management LLC boosted its holdings in shares of LeMaitre Vascular by 1,116.5% in the 3rd quarter. Voya Investment Management LLC now owns 238,914 shares of the medical instruments supplier's stock valued at $19,732,000 after acquiring an additional 219,274 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 1.0%

Shares of LMAT opened at $74.86 on Friday. The firm has a market cap of $1.71 billion, a P/E ratio of 27.48, a PEG ratio of 2.23 and a beta of 0.51. LeMaitre Vascular, Inc. has a 12 month low of $73.68 and a 12 month high of $118.01. The stock's 50 day moving average is $81.01 and its two-hundred day moving average is $93.77. The company has a current ratio of 14.60, a quick ratio of 12.54 and a debt-to-equity ratio of 0.39.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.04). LeMaitre Vascular had a return on equity of 15.33% and a net margin of 23.51%. The business had revenue of $67.97 million for the quarter, compared to analyst estimates of $67.39 million. During the same period in the previous year, the company earned $0.75 earnings per share. The company's quarterly revenue was up 11.3% compared to the same quarter last year. Analysts predict that LeMaitre Vascular, Inc. will post 2.83 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Thursday, November 19th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular's dividend payout ratio (DPR) is 36.36%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LMAT. Citizens Jmp assumed coverage on shares of LeMaitre Vascular in a research note on Thursday, November 5th. They issued a "market outperform" rating and a $110.00 price objective on the stock. Seaport Research Partners set a $110.00 target price on LeMaitre Vascular in a research note on Thursday, November 5th. Citigroup reaffirmed a "market outperform" rating on shares of LeMaitre Vascular in a report on Thursday, November 5th. Weiss Ratings cut LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, October 23rd. Finally, Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of "Hold" and a consensus price target of $108.25.

Read Our Latest Stock Report on LeMaitre Vascular

About LeMaitre Vascular

(Free Report)

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.

Featured Stories

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LeMaitre Vascular Right Now?

Before you consider LeMaitre Vascular, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.

While LeMaitre Vascular currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines